# Advanced HIV Research Report

Generated: 2025-12-26 04:12:53

## Summary

- Optimal bnAb combination: 3BNC117 + NIH45-46 + 10E8
- Mapped 20 resistance pathways
- Achieved 65.0% global HLA coverage
- Best ensemble AUC: 0.9257
- Identified 30 phylogenetic clusters
- Most conserved proteins: Vpu, Tat, Rev
- Found 610 drug repurposing candidates
- Built mutation cooccurrence networks for all drug classes

## 1. Optimal bnAb Combinations

**Recommended combination**: 3BNC117 + NIH45-46 + 10E8
- Estimated coverage: 98.9%
- Estimated potency (IC50): 1.000

## 2. Resistance Evolution Pathways

### Top Mutation Associations

- E35D <-> M36I (lift: 6.01)
- A71V <-> L90M (lift: 5.93)
- A71V <-> L10I (lift: 5.52)
- I62V <-> L90M (lift: 5.14)
- L10I <-> L90M (lift: 5.10)
- L210W <-> V118I (lift: 5.05)
- E35D <-> I62V (lift: 4.83)
- L210W <-> T215Y (lift: 4.74)
- I62V <-> M36I (lift: 4.58)
- I62V <-> I93L (lift: 4.47)

## 3. Global HLA Coverage Optimization

**Total coverage**: 65.0%

### Regional Coverage

- African: 24.2%
- Asian: 32.3%
- European: 23.1%
- Americas: 0.0%

## 4. Ensemble Prediction Models

- Best model: stacking
- Best AUC: 0.9257
- CV AUC: 0.8872 +/- 0.0243

## 5. Conservation Analysis

### Most Conserved (Best Vaccine Targets)
- Vpu
- Tat
- Rev

### Most Variable (Escape-Prone)
- Nef
- Env
- Gag

## 6. Drug Repurposing Candidates

Total candidates: 610

### Top Candidates

- **tyrosine-protein kinase ABL1 isoform a**
  - HIV protein: Tat
  - Drugs: imatinib, dasatinib, nilotinib

- **all-trans-retinol dehydrogenase**
  - HIV protein: Tat
  - Drugs: methotrexate, pemetrexed

- **adenosine receptor A3 isoform A**
  - HIV protein: Tat
  - Drugs: cetuximab, trastuzumab, rituximab

- **advanced glycosylation end product-specific recept**
  - HIV protein: Tat
  - Drugs: cetuximab, trastuzumab, rituximab

- **RAC-alpha serine/threonine-protein kinase**
  - HIV protein: Tat
  - Drugs: imatinib, dasatinib, nilotinib

